Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Why Drug Developers Need To Seek Scientific Advice From The EMA

This article was originally published in SRA

Executive Summary

Scientific advice from the European Medicines Agency, whether given alone or in parallel with health technology assessment (HTA) bodies, is an increasingly important factor in whether a new drug makes it through to marketing approval, and can double the likelihood of a positive opinion from the agency's scientific committee, the CHMP.

Advertisement
Advertisement
UsernamePublicRestriction

Register

PS118665

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel